Tesamorelin

Tesamorelin — Stabilized GHRH Analog Research Compound (≥99% Purity)

Tesamorelin is a chemically modified growth hormone-releasing hormone (GHRH) analog, built on the same 44-amino-acid backbone as native GHRH but with an added trans-3-hexenoic acid group at the N-terminus. This modification is studied for its potential to increase resistance to enzymatic breakdown, extending the compound’s research half-life relative to unmodified GHRH.

Mechanism of Action

Tesamorelin is studied for its interaction with GHRH receptors at the anterior pituitary gland, where it may stimulate cAMP-mediated signaling and downstream growth hormone secretion from somatotroph cells. Research has examined its effects on visceral fat distribution, hepatic fat fraction, and IGF-1 pathway activity, positioning it as one of the more extensively studied stabilized GHRH analogs.

Research Applications

• Visceral fat and lipid metabolism research
• Hepatic fat fraction and liver tissue studies
• IGF-1 and growth hormone axis research
• Muscle tissue density and composition studies
• Comparative studies against Sermorelin and other GHRH analogs

Specifications

• Chemical Name: Tesamorelin (GHRH Analog)
• CAS Number: 218949-48-5
• Molecular Formula: C221H366N72O67S
• Molecular Weight: ≈5136 Da
• Sequence: Modified/acylated GHRH(1-44) backbone — trans-3-hexenoyl N-terminus modification
• Purity: ≥99% (HPLC verified)
• Form: Lyophilized powder
• Available Sizes: 5mg, 10mg, 20mg

Storage & Handling

Store lyophilized Tesamorelin at −20°C, protected from light and moisture. Once reconstituted with Reconstitution Solution, store at 4°C and use within 28 days. All handling should be performed under sterile laboratory conditions by trained research personnel.

For in-vitro laboratory research use only. Not for human or animal consumption. Not a drug, supplement, or medicinal product.